AddLife AB
STO:ALIF B
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
131.8
206.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
AddLife AB
AddLife AB, a prominent player in the life sciences sector, intricately weaves its narrative through a commitment to enhancing healthcare and laboratory services across Europe. Founded in Sweden, the company has established itself as a crucial intermediary, effectively bridging the gap between manufacturers of medical devices and the healthcare institutions that require them. AddLife operates by acquiring and developing niche companies within two core segments: Labtech and Medtech. Through Labtech, it supplies essential equipment, instruments, and consumables for diagnostic and research laboratories. In Medtech, it provides a variety of healthcare logistics, medical products, and services to hospitals and care facilities, enhancing their operational efficiencies.
The financial heartbeat of AddLife rests on its adeptness at creating value through strategic acquisitions and organic growth, capitalizing on the increasing demand for innovative healthcare solutions. By continuously expanding its product portfolio and enhancing the capabilities of its subsidiaries, AddLife ensures a diversified revenue stream, mitigating risks associated with dependence on any single product or market. This approach not only fortifies their market position but also fuels their profit margins, as they deftly respond to shifting industry demands and regulatory changes. The company's shared values and decentralized business model promote entrepreneurship within its subsidiaries, fostering an environment where innovation can thrive—ensuring their continued success and substantial contribution to the evolving landscape of healthcare.
AddLife AB, a prominent player in the life sciences sector, intricately weaves its narrative through a commitment to enhancing healthcare and laboratory services across Europe. Founded in Sweden, the company has established itself as a crucial intermediary, effectively bridging the gap between manufacturers of medical devices and the healthcare institutions that require them. AddLife operates by acquiring and developing niche companies within two core segments: Labtech and Medtech. Through Labtech, it supplies essential equipment, instruments, and consumables for diagnostic and research laboratories. In Medtech, it provides a variety of healthcare logistics, medical products, and services to hospitals and care facilities, enhancing their operational efficiencies.
The financial heartbeat of AddLife rests on its adeptness at creating value through strategic acquisitions and organic growth, capitalizing on the increasing demand for innovative healthcare solutions. By continuously expanding its product portfolio and enhancing the capabilities of its subsidiaries, AddLife ensures a diversified revenue stream, mitigating risks associated with dependence on any single product or market. This approach not only fortifies their market position but also fuels their profit margins, as they deftly respond to shifting industry demands and regulatory changes. The company's shared values and decentralized business model promote entrepreneurship within its subsidiaries, fostering an environment where innovation can thrive—ensuring their continued success and substantial contribution to the evolving landscape of healthcare.
Margin Expansion: AddLife saw significant EBITA margin improvements in both Labtech and Medtech, with group EBITA margin rising to 12.7% from 11.5% last year.
Solid Revenue Growth: Sales grew 5% in Q1, driven by 12% growth in Labtech, while Medtech was flat due to last year's large U.K. instrument orders not repeating.
Strong Cash Flow: Operating cash flow improved to SEK 239 million, considerably higher than recent years, helping reduce net debt.
Debt Reduction: Net debt to EBITDA dropped to 2.8, below the company’s ambition of 3.0, supported by strong cash generation and favorable FX effects.
Acquisition Activity: AddLife completed the acquisition of Edge Medical in April and plans to ramp up acquisition activity due to the stronger balance sheet.
Portfolio Optimization: The company is actively pruning less profitable products and introducing advanced, high-margin products.
Positive Outlook: Management remains optimistic about continued margin, growth, and acquisition momentum despite some isolated market and product line weaknesses.